20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Amylyx Pharmaceuticals Inc (AMLX) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Cambridge, United States with about 136 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, AMLX reported $0M in revenue and ($145M) in net income.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $87M | $381M | $22M | $0M | $1M | $1M |
| Gross Profit | — | ($1M) | $45M | $355M | $19M | $0M | ($24M) | ($10M) |
| Gross Margin % | — | — | 51.7% | 93.3% | 86.5% | 100.0% | -3683.7% | -734.4% |
| Operating Income (EBIT) | ($162M) | ($153M) | ($315M) | $39M | ($201M) | ($83M) | ($39M) | ($14M) |
| Operating Margin % | — | — | -360.2% | 10.2% | -905.7% | -29013.3% | -6000.8% | -950.5% |
| Net Income | ($152M) | ($145M) | ($302M) | $49M | ($198M) | ($88M) | ($42M) | ($15M) |
| Net Margin % | — | — | -345.4% | 12.9% | -892.4% | -30834.7% | -6504.6% | -1039.0% |
| EBITDA | ($150M) | ($144M) | ($291M) | $55M | ($201M) | ($83M) | ($39M) | $1M |
| Earnings Per Share (EPS) | $-1.48 | $-1.53 | $-4.43 | $0.70 | $-2.98 | $-1.52 | $-0.75 | $-0.26 |
| Shares Outstanding (M) | 111M | 95M | 68M | 70M | 67M | 58M | 56M | 56M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | ($1M) | $0M |
| Gross Profit | — | $0M | $0M | ($20M) | $0M | ($22M) | ($1M) | $0M |
| Gross Margin % | — | — | — | — | — | — | 100.0% | -94.5% |
| Operating Income (EBIT) | ($46M) | ($44M) | ($37M) | ($36M) | ($43M) | ($38M) | ($41M) | ($76M) |
| Operating Margin % | — | — | — | — | — | — | 6113.4% | -18187.7% |
| Net Income | ($43M) | ($41M) | ($33M) | ($34M) | ($41M) | ($36M) | ($38M) | ($73M) |
| Net Margin % | — | — | — | — | — | — | 5646.0% | -17476.9% |
| EBITDA | ($43M) | ($41M) | ($31M) | ($34M) | ($41M) | ($36M) | ($38M) | ($72M) |
| Earnings Per Share (EPS) | $-0.39 | $-0.37 | $-0.35 | $-0.37 | $-0.46 | $-0.42 | $-0.55 | $-1.07 |
| Shares Outstanding (M) | 111M | 111M | 95M | 93M | 89M | 86M | 69M | 68M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($127M) | ($123M) | ($168M) | $12M | ($180M) | ($75M) | ($37M) | ($11M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $1M | $3M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($127M) | ($123M) | ($168M) | $11M | ($182M) | ($75M) | ($37M) | ($11M) |
| FCF Margin % | — | — | -192.1% | 2.8% | -820.5% | -26369.1% | -5668.9% | -760.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($31M) | ($37M) | ($28M) | ($30M) | ($25M) | ($40M) | ($59M) | ($42M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($31M) | ($37M) | ($28M) | ($30M) | ($25M) | ($40M) | ($59M) | ($42M) |
| FCF Margin % | — | — | — | — | — | — | 8876.4% | -9997.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $265M | $333M | $194M | $517M | $391M | $106M | $14M | $3M |
| Cash & Cash Equivalents | $49M | $227M | $77M | $170M | $63M | $50M | $13M | $3M |
| Total Liabilities | $25M | $27M | $29M | $84M | $51M | $257M | $81M | $29M |
| Total Debt (Short + Long-Term) | $1M | $1M | $2M | $2M | $2M | $0M | $1M | $15M |
| Total Shareholders' Equity | $239M | $305M | $165M | $433M | $341M | ($151M) | ($67M) | ($25M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AMLX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms